Menopausal hormone therapy (MHT), including tibolone, remains the most effective treatment for menopausal symptoms
The menstrual changes are downstream effects of metabolic changes (insulin sensitivity, weight loss), not direct hormonal interference
Hormonal changes, as mentioned above, are commonplace in rapid weight loss and can put hair into a resting phase, thereby increasing shedding
GLP-1 receptor agonist, liraglutide, ameliorates hepatosteatosis induced by anti-CD3 antibody in female mice
The peptide shelf life guide and semaglutide storage duration guide cover stability principles that apply broadly to research peptides
Rapid weight loss from GLP-1 medications like semaglutide can trigger telogen effluvium, a temporary hair-shedding condition affecting up to 40% of women in the first 36 months of therapy